DEK

Protein DEK · P35659 · DEK on Sugi Atlas →

0 patent compounds predicted against DEK, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to DEK by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus PHASE3UNKNOWN
Study of Keto Acid (KA) on Insulin Resistance in Peritoneal Dialysis (PD) Patients PHASE3COMPLETED
Evaluation of the Safety and Efficacy of LB-DTK-MV in Patients Diagnosed With Antiviral-Resistant CMV, BKV, or EBV Infection or Associated Diseases Following Anticancer Therapy or Allogeneic Hematopoietic Stem Cell Transplantation. PHASE1/PHASE2RECRUITING
Evaluation of the Safety and Efficacy of LB-DTK-BKV in Patients With BK Virus-Associated Hemorrhagic Cystitis Following Allogeneic Hematopoietic Stem Cell Transplantation. PHASE1/PHASE2NOT_YET_RECRUITING
Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy PHASE2COMPLETED
Anti-PD-1 Alone or Combined With Autologous Cell Therapy in Advanced NSCLC PHASE1/PHASE2COMPLETED
CIK-Cells in Relapsing Patients With Acute Leukemia or Myelodysplastic Syndromes After SCT. PHASE1/PHASE2UNKNOWN
Evaluation of the Possible Safety and Efficacy of Dapagliflozin in the Prophylaxis of Doxorubicin-Induced Cardiotoxicity PHASE2RECRUITING
Cytokine Induced Killer (CIK) Cells In Leukemia Patients PHASE2COMPLETED
Anti-PD-1 Alone or Combined With Autologous DC-CIK Cell Therapy in Advanced Solid Tumors PHASE1/PHASE2COMPLETED
Acetylcarnitine and Insulin Sensitivity PHASE2COMPLETED
Selective Treatment According to Molecular Subtype of Prostate Cancer PHASE2UNKNOWN
Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia PHASE1ACTIVE_NOT_RECRUITING
The Treatment of Advanced Lung Cancer With Dribbles Antigen by Targeting Activation of Tcells PHASE1UNKNOWN
Effect of Gene Variants on Dopamine Receptor Natriuretic Responses PHASE1UNKNOWN
TSL2109 Capsules in Advanced Solid Tumor Patients: Safety, Tolerability, PK and Preliminary Efficacy PHASE1RECRUITING
FORTRAS: A Study of MSK-TCR5 in People With Solid Tumor Cancers PHASE1RECRUITING
Intravenous Immune Globulin to Treat Hereditary Inclusion Body Myopathy PHASE1COMPLETED
Dendritic Cell DKK1 Vaccine for Monoclonal Gammopathy and Stable or Smoldering Myeloma EARLY_PHASE1WITHDRAWN
A Study of PD1 Combined With Dc-cik in the Treatment of Solid Tumors EARLY_PHASE1UNKNOWN
RT201(Tumor Antigen-specific Macrophage Tumor Vaccine) nanUNKNOWN
Biomarkers in Blood and Tissue Samples From Patients With Epstein-Barr Virus-Positive Hodgkin Lymphoma nanCOMPLETED
Long Term Outcome of Congenital Solitary Kidney nanUNKNOWN
Dried Fruit and Postprandial Glycemia Trial nanUNKNOWN
Mechanisms of Diabetic Nephropathy in Ecuador nanSUSPENDED
Molecular Phenotype Changes and Personalized Treatment for CRPC nanUNKNOWN
Amino Acid Bioavilability of Fava Beans nanCOMPLETED
Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation nanCOMPLETED
Assessment of ProEnkephalin to Detect Acute Kidney Injury (AKI) nanCOMPLETED
Low Carbohydrate/High Protein Diet to Improve Metabolic Health nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a DEK binder may also engage these)

ProteinNameSimilarity
Q6AXS3 1.000 Q6AXS3 →
Q7TNV0 1.000 Q7TNV0 →
Q9SMM8 0.981 Q9SMM8 →
Q6AYK5 0.978 Q6AYK5 →
LYAR Cell growth-regulating nucleolar protein 0.978 landscape →
Q4R627 0.976 Q4R627 →
Q66T72 0.974 Q66T72 →
Q76MT4 0.974 Q76MT4 →
Q812D1 0.973 Q812D1 →
E1BTG2 0.973 E1BTG2 →
Q9SU25 0.972 Q9SU25 →
Q84JB7 0.972 Q84JB7 →
O60934 0.972 O60934 →
Q7ZWE3 0.971 Q7ZWE3 →
Q99JF8 0.971 Q99JF8 →
I1HNB2 0.971 I1HNB2 →
Q61029 0.971 Q61029 →
Q04870 0.971 Q04870 →
P15205 0.971 P15205 →
Q8HXY9 0.971 Q8HXY9 →
Q3THK3 0.970 Q3THK3 →
Q53F19 0.970 Q53F19 →
Q4ADK7 0.970 Q4ADK7 →
Q5EA53 0.970 Q5EA53 →
Q08288 0.970 Q08288 →
Q5XXA9 0.970 Q5XXA9 →
Q4LE39 0.969 Q4LE39 →
Q5ZM19 0.969 Q5ZM19 →
GTF2F1 General transcription factor IIF subunit 1 0.969 landscape →
Q28G87 0.969 Q28G87 →